Sanochemia Pharmazeutika AG
http://www.sanochemia.at/en/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sanochemia Pharmazeutika AG
Finance Watch: VC Mega-Rounds Are Alive And Well
Private Company Edition: Also, Catalio closed a $381m venture capital fund and OrbiMed’s SEC filings indicate it is in the process of raising $4.75bn across three new funds. Dianthus launched with $100m and Tubulis closed a $63m series B round.
Finance Watch: HilleVax, Belite Bio Launch First Two Biopharma IPOs In Q2
Also, Cytovia will go public via SPAC merger, Nkarta capitalized on its positive early NK cell therapy data with a $230m offering, and venture capital mega-rounds include $220m for Reify, $110m for Satellite Bio and $100m for OMass Therapeutics.
Finance Watch: Neuron23 Adds $100m To Take First Drug Into The Clinic
Private Company Edition: Westlake Village BioPartners-founded Neuron23 will take the LRRK2 inhibitor NEU-723 for Parkinson’s disease into human testing before the end of 2022. Also, Celsius raised $83m in fresh VC cash and ITM added another €33m to its recent €25m equity financing.
Hyloris Outlines Ambitious Growth Strategy During Full-Year Results
Hyloris expects to expand its portfolio to around 30 candidates by 2024, bolstered by €50m in cash and cash equivalents as of the end of 2021.
Company Information
- Industry
- Biotechnology
- Contract Research, Toxicology Testing-CRO
- Distributors
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Medical Devices
-
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
-
Diagnostic Imaging Equipment & Supplies
- Other Names / Subsidiaries
-
- Alvetra et al Werfft GmbH
- SANOCHEMIA Diagnostics Deutschland GmbH
- SANOCHEMIA Diagnostics International Ltd.